BIOSECURE returns to US pharma agenda with 2.0 update
After a year in the shadows, the controversial BIOSECURE Act could make a return following an endorsement of a revised…
News
AstraZeneca inks Trump drug pricing deal amid tariff threats
J&J in talks to acquire Protagonist Therapeutics
FDA approves Teva and Medincell’s bipolar I disorder treatment
BMS expands CAR-T portfolio with $1.5bn Orbital buyout
AstraZeneca sets $4.5bn Virginia API plant construction in motion
Flu vaccine uptake increases 28% in England
FDA approves Celltrion’s Eydenzelt for eye diseases
